Israeli startup develops AI to detect 250 genetic diseases in fetuses from maternal b Gaylord Contreras | usagoldmines.com

IdentifAI, an Israeli health-tech firm, has developed a non-invasive prenatal testing (NIPT) expertise able to figuring out 250 hereditary genetic issues from a maternal blood pattern. The breakthrough builds on the analysis of Professor Noam Shomron of Tel Aviv College, a number one professional in genetics and bioinformatics.

The corporate’s method isolates fetal DNA from maternal DNA in blood samples and makes use of synthetic intelligence and machine studying to conduct full genetic sequencing from as early as 9 weeks of being pregnant. This marks a big enlargement of present NIPT capabilities, that are restricted to detecting about 25 genetic situations reminiscent of Tay-Sachs and cystic fibrosis.

Scientific trials at Israel’s Beilinson and Meir hospitals demonstrated the system’s accuracy. In exams involving 18 pregnant girls, IdentifAI’s expertise appropriately recognized fetal dangers, with outcomes matching these of amniocentesis, a extra invasive process. These findings had been revealed in Prenatal Prognosis, a number one journal within the area.

The corporate is conducting additional trials in the USA, together with a current examine at Columbia College Medical Middle. Seven further U.S. medical facilities are set to take part in upcoming trials.

Whereas conventional amniocentesis stays the gold commonplace for prenatal genetic testing, its invasive nature poses dangers to each the mom and fetus. NIPTs have gained reputation as a safer different however have been constrained by their restricted scope. IdentifAI’s expertise, able to detecting mutations in single DNA bases, goals to handle this hole.

The marketplace for NIPTs is anticipated to develop considerably, from its present $6 billion valuation to $19 billion by 2030, pushed by advances in expertise and elevated demand for non-invasive options.

To this point, IdentifAI has raised $6.5 million from eHealth Ventures specializing in healthtech investments, Shizim Fund, and extra buyers, together with grants from the Israel Innovation Authority. The corporate employs 15 individuals in its Tel Aviv places of work.